SCHEMBL16748423

SCHEMBL16748423

Cc1ccc(Nc2nc(N)nc(-n3c(C4CC4)nc4cc(F)ccc43)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYBB P04839 1/20 0.43
NOX5 Q96PH1 1/20 0.43
NOX3 Q9HBY0 1/20 0.43
NOX4 Q9NPH5 1/20 0.43
NOX1 Q9Y5S8 1/20 0.43
BMI1 P35226 6/20 0.42
DHFR P00374 3/20 0.40
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
JAK2 O60674 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
GAA P10253 1/20 0.38
BLM P54132 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740843 0.92 BMI1 (0.51) CYBBNOX5NOX3NOX4NOX1
SCHEMBL16748418 0.90 BMI1 (0.42) BMI1DHFRMAPK1SMN1; SMN2BLM
SCHEMBL16748448 0.90 BMI1 (0.42) BMI1DHFRRAB9ANPC1SMN1; SMN2
SCHEMBL16748422 0.90 BMI1 (0.49) BMI1DHFRL3MBTL1RAB9ANPC1
SCHEMBL16748493 0.89 BMI1 (0.56) BMI1DHFRSMN1; SMN2BLMLMNA
SCHEMBL16748497 0.86 BMI1 (0.51) BMI1L3MBTL1ALDH1A1MAPT
SCHEMBL16740760 0.86 BMI1 (0.49) CYBBNOX5NOX3NOX4NOX1
SCHEMBL16740799 0.83 BMI1 (0.44) CYBBNOX5NOX3NOX4NOX1
SCHEMBL16740849 0.82 BMI1 (0.51) BMI1DHFRMAPK1SMN1; SMN2BLM
SCHEMBL16748514 0.82 BMI1 (0.40) BMI1DHFRGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B CYBB 4251/4885NOX5 3227/4885NOX3 3963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.